Tanshinone I suppresses hepatocellular carcinoma cells growth through targeting DNA double-strand break repair

References

• Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–7. doi:10.1097/CM9.0000000000002108.
   PubMed Web of Science ®Google Scholar
• Crocetti L, Bargellini I, Cioni R. Loco-regional treatment of HCC: current status. Clin Radiol. 2017;72(8):626–635. doi:10.1016/j.crad.2017.01.013.
   PubMed Web of Science ®Google Scholar
• Kirstein MM, Wirth TC. Multimodal treatment of hepatocellular carcinoma. Internist (Berl). 2020;61(2):164–169. doi:10.1007/s00108-019-00722-x.
   PubMed Web of Science ®Google Scholar
• Nia A, Dhanasekaran R. Genomic landscape of HCC. Curr Hepatol Rep. 2020;19(4):448–461. doi:10.1007/s11901-020-00553-7.
   PubMedGoogle Scholar
• Chen W, Chiang CL, Dawson LA. Efficacy and safety of radiotherapy for primary liver cancer. Chin Clin Oncol. 2021;10(1):9. doi:10.21037/cco-20-89.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Yang SF, Chang CW, Wei RJ, Shiue YL, Wang SN, Yeh YT. Involvement of DNA damage response pathways in hepatocellular carcinoma. Biomed Res Int. 2014;2014:153867. doi:10.1155/2014/153867.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen. 2017;58(5):235–263. doi:10.1002/em.22087.
   PubMed Web of Science ®Google Scholar
• Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73(1):39–85. doi:10.1146/annurev.biochem.73.011303.073723.
   PubMed Web of Science ®Google Scholar
• Nambiar M, Raghavan SC. How does DNA break during chromosomal translocations? Nucleic Acids Res. 2011;39(14):5813–5825. doi:10.1093/nar/gkr223.
   PubMed Web of Science ®Google Scholar
• Zhu C, Mills KD, Ferguson DO, Lee C, Manis J, Fleming J, Gao Y, Morton CC, Alt FW. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell. 2002;109(7):811–821. doi:10.1016/S0092-8674(02)00770-5.
   PubMed Web of Science ®Google Scholar
• Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12(12):801–817. doi:10.1038/nrc3399.
   PubMed Web of Science ®Google Scholar
• Wang C, Tang H, Geng A, Dai B, Zhang H, Sun X, Chen Y, Qiao Z, Zhu H, Yang J, et al. Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors. Proc Natl Acad Sci USA. 2020;117(42):26356–26365. doi:10.1073/pnas.2002917117.
   PubMed Web of Science ®Google Scholar
• Yang S, Wang XQ. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance. Bmc Cancer. 2017;17(1):344. doi:10.1186/s12885-017-3345-y.
   PubMedGoogle Scholar
• Zhou J, Jiang YY, Chen H, Wu YC, Zhang L. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway. Cell Prolif. 2020;53(2):e12739. doi:10.1111/cpr.12739.
   PubMed Web of Science ®Google Scholar
• Wang X, Fan J, Ding X, Sun Y, Cui Z, Liu W. Tanshinone I inhibits IL-1beta-induced apoptosis, inflammation and extracellular matrix degradation in chondrocytes CHON-001 cells and attenuates murine osteoarthritis. Drug Des Devel Ther. 2019;13:3559–3568. doi:10.2147/DDDT.S216596.
   PubMed Web of Science ®Google Scholar
• Yang L, Zhou G, Liu J, Song J, Zhang Z, Huang Q, Wei F. Tanshinone I and Tanshinone IIA/B attenuate LPS-induced mastitis via regulating the NF-kappaB. Biomed Pharmacother. 2021;137:111353. doi:10.1016/j.biopha.2021.111353.
   PubMed Web of Science ®Google Scholar
• Luo H, Vong CT, Chen H, Gao Y, Lyu P, Qiu L, Zhao M, Liu Q, Cheng Z, Zou J, et al. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chin Med. 2019;14(1):48. doi:10.1186/s13020-019-0270-9.
   PubMed Web of Science ®Google Scholar
• Zhang F, Tang H, Jiang Y, Mao Z. The transcription factor GATA3 is required for homologous recombination repair by regulating CtIP expression. Oncogene. 2017;36(36):5168–5176. doi:10.1038/onc.2017.127.
   PubMed Web of Science ®Google Scholar
• Sharma A, Singh K, Almasan A. 2012. Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol. 920:613–626.
   PubMedGoogle Scholar
• Zimmermann M, de Lange T. 53BP1: pro choice in DNA repair. Trends Cell Biol. 2014;24(2):108–117. doi:10.1016/j.tcb.2013.09.003.
   PubMed Web of Science ®Google Scholar
• Setiaputra D, Durocher D. Shieldin – the protector of DNA ends. EMBO Rep. 2019;20(5). doi:10.15252/embr.201847560.
   PubMed Web of Science ®Google Scholar
• Cao L, Xu X, Bunting SF, Liu J, Wang RH, Cao LL, Wu JJ, Peng TN, Chen J, Nussenzweig A, et al. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell. 2009;35(4):534–541. doi:10.1016/j.molcel.2009.06.037.
   PubMed Web of Science ®Google Scholar
• Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010;141(2):243–254. doi:10.1016/j.cell.2010.03.012.
   PubMed Web of Science ®Google Scholar
• Wang X, Yang Y, Liu X, Gao X. 2020. Pharmacological properties of tanshinones, the natural products from Salvia miltiorrhiza. Adv Pharmacol. 87:43–70.
   PubMedGoogle Scholar